

Practitioner's Docket No. MPI97-035CP1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Acton, Susan L., et al.
Application No.: 09/163,648 Group No.:
Filed: September 30, 1998 Examiner:
For: ANGIOTENSIN CONVERTING ENZYME HOMOLOG AND
THERAPEUTIC AND DIAGNOSTIC USES THEREFOR

RECEIVED

OCT 30 2002

TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231

**REVOCATION OF PRIOR POWERS OF ATTORNEY
AND APPOINTMENT OF NEW POWER OF ATTORNEY**

Dear Sir:

MILLENNIUM PHARMACEUTICALS, INC., the Assignee of the entire right, title and interest in the above-identified application by virtue of the Assignment document filed with the United States Patent and Trademark Office on February 16, 1999, at Reel 9765, Frame 0718, revokes all Powers of Attorney with respect to that application heretofore granted and appoints the below listed attorneys with full power of substitution and revocation to prosecute this application and to transact all business in the Patent Office connected therewith.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☐ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.
37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☐ with sufficient postage as first class mail.

- ☐ as "Express Mail Post Office to Addressee"
Mailing Label No. _____

TRANSMISSION

- ☒ transmitted by facsimile to the Patent and Trademark Office.

Signature

Maria Laccotripe
Maria Laccotripe Zacharakis, Ph.D.
(type or print name of person certifying)

Date: 10/22/02

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b) "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MP197-035CP1

Scott A. Brown, Reg. No. 32,724; Ian R. Silverman, Reg. No. 37,443; Susan M. Perkins, Reg. No. 36,405; Jean M. Silveri, Reg. No. 39,030; Allan N. Kutzenco, Reg. No. 38,945; Theodore R. Allen, Reg. No. 41,578; Kerri Pollard Schray, Reg. No. 47,066, Tracy M. Sioussat, Reg. No. 51,609; and Steven A. Bossone, Reg. No. 51,196;

all of Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, Massachusetts 02139, United States of America.

Please direct all future correspondence to:

Intellectual Property Group
MILLENNIUM PHARMACEUTICALS, INC.
75 Sidney Street
Cambridge, MA 02139

and direct all telephone calls to Jean M. Silveri at (617) 679-7336.

MILLENNIUM PHARMACEUTICALS, INC.

By: 

Typed Name: Scott A. Brown

Title: Vice President, Chief Patent Counsel

Dated: October 17, 2002